Replies to post #627662 on NorthWest Biotherapeutics Inc (NWBO)

[brazen22]

The median overall survival for patients with newly diagnosed glioblastoma receiving DCVax-L was 19.3 months. For patients with recurrent glioblastoma, the median overall survival after receiving DCVax-L was 13.2 months, So I don't think waiting for patients to die casued the trial to take so long